QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:MDXG

MiMedx Group (MDXG) Stock Forecast, Price & News

$7.70
-0.08 (-1.03%)
(As of 09/21/2023 ET)
Compare
Today's Range
$7.57
▼
$7.75
50-Day Range
$6.71
▼
$8.16
52-Week Range
$2.43
▼
$8.60
Volume
388,370 shs
Average Volume
686,714 shs
Market Capitalization
$894.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

MiMedx Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.3% Upside
$12.50 Price Target
Short Interest
Healthy
2.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
625.00%
From $0.04 to $0.29 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

464th out of 961 stocks

Surgical & Medical Instruments Industry

49th out of 95 stocks

See Top Rated MarketRank™ Stocks Here

MDXG stock logo

About MiMedx Group (NASDAQ:MDXG) Stock

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MDXG Price History

MDXG Stock News Headlines

August 31, 2023 | msn.com
Mimedx Group (MDXG) Price Target Increased by 19.14% to 12.30
August 15, 2023 | finance.yahoo.com
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
September 21, 2023 | Behind the Markets (Ad)
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
August 10, 2023 | seekingalpha.com
MiMedx Group, Inc. 2023 Q2 - Results - Earnings Call Presentation
August 2, 2023 | finance.yahoo.com
MDXG: Beat and a Raise
August 2, 2023 | finance.yahoo.com
Q2 2023 MiMedx Group Inc Earnings Call
August 2, 2023 | finanznachrichten.de
MiMedx Group, Inc: MIMEDX Announces Second Quarter 2023 Operating and Financial Results
August 2, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for MiMedx Group (MDXG)
September 21, 2023 | Behind the Markets (Ad)
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
August 1, 2023 | finance.yahoo.com
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
July 25, 2023 | seekingalpha.com
MiMedx Stock: Strategic Realignment Can Unlock Value
July 18, 2023 | finance.yahoo.com
MIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1
July 11, 2023 | finance.yahoo.com
MIMEDX Announces Favorable Ruling in Putative Securities Class Action Case
July 6, 2023 | msn.com
Mimedx Group (MDXG) Price Target Decreased by 11.76% to 9.56
July 5, 2023 | finanznachrichten.de
MiMedx Group, Inc: MIMEDX Appoints Doug Rice as Chief Financial Officer
July 5, 2023 | finance.yahoo.com
MIMEDX Appoints Doug Rice as Chief Financial Officer
June 28, 2023 | msn.com
MiMedx Group climbs 4%, reports CEO buying $640K stock
June 22, 2023 | finance.yahoo.com
MDXG: KOA Program Discontinued
June 22, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: MiMedx Group (MDXG), Arbutus Biopharma (ABUS)
June 21, 2023 | markets.businessinsider.com
MiMedx Targets Profitability with Strategic Realignment, Suspends Knee Osteoarthritis Program Activities
June 20, 2023 | marketwatch.com
MiMedx Group Plans Strategic Realignment to Focus on Wound and Surgical Business
June 20, 2023 | finance.yahoo.com
MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability
June 20, 2023 | msn.com
MiMedx pulls plug on knee osteoarthritis, regenerative medicine programs
June 20, 2023 | finance.yahoo.com
MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability
May 25, 2023 | finance.yahoo.com
Breakeven On The Horizon For MiMedx Group, Inc. (NASDAQ:MDXG)
May 18, 2023 | benzinga.com
MiMedx Group President Trades Company's Stock
May 6, 2023 | seekingalpha.com
MiMedx's Post-Q1 2023 Surge Could Result In Profit-Taking
See More Headlines
Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MDXG Company Calendar

Last Earnings
11/02/2021
Today
9/21/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDXG
CUSIP
N/A
CIK
1376339
Web
www.mimedx.com
Phone
(770) 651-9100
Fax
678-384-6741
Employees
867
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+61.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
193.25
P/E Growth
N/A
Net Income
$-30,200,000.00
Net Margins
-6.58%
Pretax Margin
-4.26%
Return on Equity
N/A
Return on Assets
-11.27%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.18
Quick Ratio
2.80

Sales & Book Value

Annual Sales
$267.84 million
Price / Sales
3.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.16) per share
Price / Book
-48.31

Miscellaneous

Outstanding Shares
116,110,000
Free Float
93,003,000
Market Cap
$897.53 million
Optionable
Optionable
Beta
1.61
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. William F. Hulse IV (Age 49)
    Gen. Counsel & Chief Admin. Officer
    Comp: $677.36k
  • Dr. Robert Benjamin Stein M.D. (Age 72)
    Ph.D., Pres of Regenerative Medicine & Biologics Innovation
    Comp: $639.28k
  • Mr. Joseph H. Capper (Age 59)
    CEO & Director
  • Mr. Douglas C. Rice CPA (Age 57)
    Chief Financial Officer
  • Mr. Scott M. Turner (Age 57)
    Sr. VP of Operations & Procurement
  • Mr. William L. Phelan
    Sr. VP & Chief Accounting Officer
  • Mr. Matthew M. Notarianni
    Head of Investor Relations
  • Mr. Mark P. Graves (Age 57)
    Sr. VP & Chief Compliance Officer
  • Hilary Dixon
    VP of Investor Relations & Corp. Strategic Communications
  • Ms. Kate Surdez
    Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MDXG Stock - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings or view top-rated stocks.

What is MiMedx Group's stock price forecast for 2023?

2 brokerages have issued 1-year price targets for MiMedx Group's stock. Their MDXG share price forecasts range from $11.00 to $14.00. On average, they expect the company's share price to reach $12.50 in the next year. This suggests a possible upside of 61.7% from the stock's current price.
View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts.

How have MDXG shares performed in 2023?

MiMedx Group's stock was trading at $2.78 on January 1st, 2023. Since then, MDXG shares have increased by 178.1% and is now trading at $7.73.
View the best growth stocks for 2023 here.

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our MDXG earnings forecast.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04. The firm earned $63.07 million during the quarter, compared to the consensus estimate of $60.26 million. During the same period in the prior year, the business earned ($0.48) earnings per share.

What ETF holds MiMedx Group's stock ?

Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio.

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.99%), Paradigm Capital Management Inc. NY (3.00%), State Street Corp (2.90%), Geode Capital Management LLC (2.01%), Richmond Brothers Inc. (1.37%) and Cannell Capital LLC (0.95%). Insiders that own company stock include Mark Graves, Peter M Carlson, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $7.73.

How much money does MiMedx Group make?

MiMedx Group (NASDAQ:MDXG) has a market capitalization of $897.53 million and generates $267.84 million in revenue each year. The company earns $-30,200,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does MiMedx Group have?

The company employs 867 workers across the globe.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The official website for the company is www.mimedx.com. The company can be reached via phone at (770) 651-9100, via email at investorrelations@mimedx.com, or via fax at 678-384-6741.

This page (NASDAQ:MDXG) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -